BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $45.99M rose 98.8% year over year, ahead of the +90.5% change in trailing-twelve-month operating expenses. Sequentially, it rose 6.0% from the prior quarter. Over 3 fiscal years it compounded at +3360.1% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +98.8% holds above the trailing-twelve-month pace of +90.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 145.82M USD
- Year-over-year change
- +80.3%
- 4-year CAGR
- +661.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 145.82M | +80.3% |
| FY2024 | 2024-12-31 | 80.86M | +24.8% |
| FY2023 | 2023-12-31 | 64.77M | +1839985.2% |
| FY2022 | 2022-12-31 | 3.52K | -91.9% |
| FY2021 | 2021-12-31 | 43.36K | — |
Operating Expenses vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +90.5% is the 3rd highest of 10, against a peer median of +23.2%.
- Over three fiscal years its annual growth of +3360.1% compares with a peer median of +28.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $317.52M USD | +142.5% | +109.8% | 45.2% | |
| LTM Mar 2026 | $270.62M USD | -24.2% | +22.1% | 132.1% | |
| LTM Jun 2026 | $261.54M USD | +14.7% | +83.3% | 249.1% | |
| LTM Sep 2026 | $251.17M USD | +16.0% | -10.8% | — | |
| LTM Mar 2026 | $234.45M USD | +23.2% | +17.9% | 166.9% | |
| LTM Mar 2026 | $229.74M USD | +420.0% | +71.3% | 98.9% | |
| LTM Sep 2026 | $227.59M USD | +29.2% | +8.0% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $169.24M USD | +70.9% | — | 175.8% |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $168.68M USD | +90.5% | +3360.1% | — |
| LTM Mar 2026 | CHF 69.81M CHF | -10.3% | +34.7% | 13851.6% | |
| Peer median (excluding BBOT) | — | +23.2% | +28.4% | 166.9% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.